<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Percutaneous carotid artery stenting
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Percutaneous carotid artery stenting
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Percutaneous carotid artery stenting
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey Jim, MD, MPHS, FACS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John F Eidt, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joseph L Mills, Sr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kathryn A Collins, MD, PhD, FACS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 06, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H3258306045">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with indications for carotid revascularization, treatment options include carotid endarterectomy or carotid artery stenting (CAS), which is most commonly accomplished with stent delivery using a transfemoral (ie, TF-CAS) approach, but other percutaneous approaches (transaxillary, transcervical, transradial) have also been described.
        </p>
        <p>
         Percutaneous CAS, and more specifically TF-CAS, has advantages and disadvantages and, as with other approaches to carotid artery revascularization, the patient's anatomy must meet specific anatomic requirements to undergo the procedure safely.
        </p>
        <p>
         The technical aspects and outcomes of primarily TF-CAS are reviewed, with aspects of other percutaneous approaches provided where relevant.
        </p>
        <p>
         Transcarotid artery revascularization (TCAR) requires a surgical cutdown to expose the common carotid artery for device placement and uses cerebral protection with flow reversal during introduction of a carotid stent. Because TCAR eliminates the risks associated with traversing the aortic arch, TCAR is gaining enthusiasm as an alternative approach to CAS among vascular clinicians and is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/127009.html" rel="external">
          "Transcarotid artery revascularization"
         </a>
         .).
        </p>
        <p>
         A comparison of CAS techniques is also provided separately. (See
         <a class="medical medical_review" href="/z/d/html/1104.html" rel="external">
          "Overview of carotid artery stenting", section on 'Approach to carotid artery stenting'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1886363264">
         <span class="h1">
          DEVICES USED FOR CAROTID REVASCULARIZATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         CAS systems were developed in the 1990s as a less invasive alternative to carotid endarterectomy (CEA) for carotid artery stenosis [
         <a href="#rid1">
          1
         </a>
         ]. An endovascular approach is associated with fewer perioperative complications compared with open surgery for other vascular diseases, and it was felt that the same would be the case for CEA. A reduced rate of complications would be especially pertinent for patients deemed to be at "high risk" for CEA related to specific anatomic or physiologic risk factors [
         <a href="#rid2">
          2
         </a>
         ]. While the risk of some perioperative complications was reduced with CAS, the risk for stroke was increased for CAS in trials comparing CEA with predominantly transfemoral CAS (TF-CAS). Over time, stroke rates associated with TF-CAS have decreased but remain concerning for certain subsets of patients. In an effort to reduce the potential for embolization and the risk of periprocedural stroke, refinement in carotid stents, embolic protection devices, and techniques are ongoing.
        </p>
        <p class="headingAnchor" id="H1935396963">
         <span class="h2">
          Carotid stent devices
         </span>
         <span class="headingEndMark">
          —
         </span>
         Carotid stents can be grossly divided into two groups: open-cell architecture and closed-cell architecture [
         <a href="#rid3">
          3,4
         </a>
         ]. With closed-cell stents, the stent struts are all interconnected, which is not the case for open-cell stents. As such, this architectural difference makes open-cell stents more flexible, and they may be more often chosen for more complex, angulated lesions or tortuous anatomy that may make delivery of the stent challenging. While closed-cell stents may be less flexible, they do have smaller free cell area between the stent struts, leaving smaller gaps uncovered, and may be more resistant to particle penetration that can lead to embolization [
         <a href="#rid5">
          5
         </a>
         ]. A novel dual layer stent, which is available for use outside of the United States, has reported good early results [
         <a href="#rid6">
          6,7
         </a>
         ]. This "covered" stent is designed to minimize and control plaque prolapse, thereby preventing plaque-related embolism after stent placement. In one trial, this mesh stent appeared to reduce the number and volume of new lesions identified on diffusion-weighted magnetic resonance imaging (DW-MRI) performed 2 days and 30 days after the procedure [
         <a href="#rid8">
          8
         </a>
         ]. However, longer follow-up is needed to determine whether there is any sustained benefit.
        </p>
        <p>
         Data from one trial, various retrospective studies, and registry reviews have failed to demonstrate any clinically important advantages for one stent type over another [
         <a href="#rid9">
          9-12
         </a>
         ]. A systematic review that included nine predominantly retrospective studies did not find any significant differences in periprocedural (30-day) cerebrovascular complications comparing open- with closed-cell stent designs [
         <a href="#rid9">
          9
         </a>
         ]. In a review of 740 patients who received carotid stents from the International Carotid Stenting Study (ICSS), the rate of ipsilateral stroke beyond 30 days was similar for each group [
         <a href="#rid10">
          10
         </a>
         ]. However, the rate of restenosis ≥50 percent occurred in significantly fewer patients who received open- compared with closed-stent designs (36 versus 46 percent; hazard ratio [HR] 0.68, 95% CI 0.53-0.88), and there was a trend toward a reduced rate of severe stenosis (≥70 percent) or occlusion for the open-stent design (8.6 versus 12.7 percent; HR 0.63, 95% CI 0.37-1.05).
        </p>
        <p>
         The dual-layered stent combines a stent frame with a micromesh lattice to provide better coverage of the carotid plaque compared with conventional stent designs. In the SCAFFOLD trial, 265 patients were treated with a 30-day stroke rate of 1.1 percent [
         <a href="#rid13">
          13
         </a>
         ]. In a meta-analysis looking at four single-arm prospective studies evaluating two different dual-layered stents, the 30-day stroke rate was 1.25 percent [
         <a href="#rid14">
          14
         </a>
         ]. While the early results are promising, longer follow-up in these patients is needed to ensure that subsequent rates of stroke, stent thrombosis, or restenosis are not higher compared with other stents.
        </p>
        <p>
         There are no data supporting the use of drug-eluting stents or drug-coated balloons in treating carotid stenosis. The rate of restenosis following TF-CAS with bare metal stents is generally low.
        </p>
        <p class="headingAnchor" id="H1004553144">
         <span class="h2">
          Embolic protection devices
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are two basic types of embolic protection devices (EPDs): distal filters and proximal occlusion (flow arrest, flow reversal) [
         <a href="#rid15">
          15-23
         </a>
         ]. Filter devices are used in the majority of percutaneous CAS procedures.
        </p>
        <p>
         In a review of over 24,000 patients undergoing CAS, 74 percent were performed using TF-CAS with distal embolic protection, 2.3 percent using TF-CAS with proximal balloon occlusion, and 22.9 percent using transcarotid artery revascularization (TCAR) with flow reversal [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3703339738">
         <span class="h3">
          Distal filters
         </span>
         <span class="headingEndMark">
          —
         </span>
         Distal filter designs allow continuous antegrade flow through the internal carotid artery during stent placement and are designed to catch debris dislodged during stent placement. Although filter devices are the most commonly used type of EPD for percutaneous CAS, they have several disadvantages [
         <a href="#rid3">
          3,25-27
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         They must pass unprotected across the stenosis, and tight lesions may require additional unprotected predilatation before the filter can be placed, a process that may dislodge emboli.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There may be incomplete apposition of the filter device against the arterial wall, which may lead to incomplete capture of embolizing particles.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presence of the filter in the distal internal carotid artery may induce vasospasm that can severely compromise outflow and cause stroke if prolonged. Spasm can be treated with an intra-arterial vasodilator such as
         <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">
          nitroglycerin
         </a>
         or
         <a class="drug drug_general" data-topicid="9739" href="/z/d/drug information/9739.html" rel="external">
          papaverine
         </a>
         , but such treatment can lead to systemic hypotension.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Filters can cause complications related to vessel wall injury or to difficulty in removal of the device once the carotid stent has been placed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         By their inherent design that allows for flow through the filter, all filters allow some particles to pass into the internal carotid artery and cerebral circulation. In some instances, particles as large as 200 to 250 microns can pass, potentially resulting in small or minor stroke.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H271065286">
         <span class="h3">
          Proximal occlusion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Proximal occlusion devices redirect the flow of blood, including particulate matter, away from the internal carotid artery. Proximal occlusion is used in &lt;5 percent of TF-CAS procedures [
         <a href="#rid24">
          24
         </a>
         ]. Proponents of proximal devices emphasize that the embolic protection system is set up proximal to the lesion before intervention, which avoids unprotected engagement of the lesion as is necessary with distal filters. In a systematic review of proximal devices, the pooled rate of periprocedural adverse events was low at 1.7 percent [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         There are two general categories of proximal occlusion.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Flow arrest designs deploy occlusion balloons in the external carotid artery and common carotid artery, which results in cessation of flow in the internal carotid artery [
         <a href="#rid29">
          29-31
         </a>
         ]. The proximal internal carotid artery is suctioned to remove debris prior to deflating the occlusion balloons. A single flow arrest system is commercially available (ie, MoMA).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Flow reversal designs promote retrograde flow, with blood directed from the internal carotid artery through the device into the venous circulation. The flow reversal device originally used for TF-CAS has not been commercially available for several years.
        </p>
        <p>
        </p>
        <p>
         Of note, the flow reversal systems require traversing the aortic arch to access the carotid artery. One flow arrest or occlusion system (eg, MoMa) that has been used with TF-CAS requires traversing the aortic arch to access the common carotid artery, but the internal carotid lesion is not traversed with the wire platform until flow occlusion is established. Another flow reversal system (Gore) was withdrawn from the market and is no longer commercially available. The flow reversal system designed for use with TCAR provides flow reversal before the lesion is crossed and with delivery of the flow reversal system and carotid stent directly through a common carotid artery cutdown, embolization from an aortic arch source is eliminated. (See
         <a class="medical medical_review" href="/z/d/html/127009.html" rel="external">
          "Transcarotid artery revascularization", section on 'Transcarotid stenting system'
         </a>
         .)
        </p>
        <p>
         Disadvantages associated with proximal embolic protection devices include [
         <a href="#rid26">
          26
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         They are larger than filter-type devices (6 French), requiring larger sheaths (9 French) to be placed into the femoral artery with potential higher risk of access-related complications.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cerebral ischemia can occur with proximal occlusion. Regardless of the design, some patients will be intolerant to the transient loss of flow up the internal carotid artery [
         <a href="#rid32">
          32
         </a>
         ]. Using a flow arrest system, the rate of intolerance was as high as 30 percent in one study [
         <a href="#rid32">
          32
         </a>
         ]. The rates of intolerance are much lower for flow reversal devices, ranging from &lt;1 to 2.4 percent [
         <a href="#rid31">
          31,33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Injury to the common and external carotid arteries can occur with balloon inflation.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3515637388">
         <span class="h3">
          Effectiveness of embolic protection
         </span>
         <span class="headingEndMark">
          —
         </span>
         A benefit for the use of EPDs during TF-CAS in preventing periprocedural stroke and death has not definitively been established, and the available evidence consisting of randomized trials, retrospective reviews, and registry studies has been conflicting. In addition, the clinical significance of any new microvascular lesions, which is often used to compare devices, has yet to be determined [
         <a href="#rid25">
          25
         </a>
         ]. Nevertheless, many consider the use of an EPD to be standard of care. In the United States, the use of an EPD is mandatory for reimbursement for CAS.
        </p>
        <p class="headingAnchor" id="H3536137366">
         <span class="h4">
          Stroke rates with versus without
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data from some [
         <a href="#rid34">
          34,35
         </a>
         ], but not all [
         <a href="#rid36">
          36
         </a>
         ], carotid stent trials (predominantly TF-CAS) suggest that EPDs are not effective for preventing symptomatic stroke or new ischemic brain lesions. In a meta-analysis that included two trials (Stent-Protected Angioplasty versus Carotid Endarterectomy [SPACE], Endarterectomy versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis [EVA-3S]), the combined endpoint of death or any stroke was similar for CAS with compared to without cerebral protection (odds ratio 0.77, 95% CI 0.41-1.46) [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the SPACE trial, the decision to use an EPD was left to the discretion of the enrolling center; only 27 percent of patients undergoing stenting received embolic protection. Four different EPDs were used. In a prespecified subgroup analysis, there was no significant difference in the 30-day outcome of ipsilateral stroke or death for those who underwent CAS with (n = 151) compared to without (n = 416) embolic protection (7.3 and 6.7 percent, respectively) [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the EVA-3S trial, which began enrollment in 2000, embolic protection was initiated in 2003, but the study was stopped in 2005. The 30-day risk of stroke and death was lower for those undergoing CAS with protection compared with those undergoing CAS without protection (8 versus 25 percent) [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         One explanation for the inability of EPDs to prevent all perioperative strokes is that they do not prevent all emboli from reaching the distal cerebral vessels.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The risk of stroke may be related to embolic load. This was suggested in a study that analyzed aspirated debris from 54 patients who had CAS with proximal balloon occlusion [
         <a href="#rid39">
          39
         </a>
         ]. The risk of a neurologic event was associated with higher numbers of relevant particles, larger maximum particle diameters, and larger maximum particle areas.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Filter type EPDs may paradoxically increase the microembolic load by leading to disintegration of macroemboli into smaller microemboli that can pass through the micropores of the EPD or through gaps that exist between the EPD and the arterial wall [
         <a href="#rid40">
          40
         </a>
         ]. In addition, thrombus may form on the distal filter surface or on the tip of the EPD wire or result from EPD-related microtrauma to the vascular wall.
        </p>
        <p>
        </p>
        <p>
         It is possible that some or all of the reduction in complication rates attributed to EPDs in observational studies is related to improvements in stent technology and the increasing experience of operators over time rather than the use of the EPDs [
         <a href="#rid41">
          41,42
         </a>
         ]. In support of this hypothesis, a single-center case series of 528 patients who had CAS without protection over a five-year study period noted a significant reduction in the 30-day minor stroke rate in the fifth year compared with the first year (3.1 versus 7.1 percent, respectively) [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         In a 2020 review of over 24,000 patients undergoing CAS, among 464 matched pairs undergoing TF-CAS with distal embolic protection or TF-CAS with proximal balloon occlusion, adverse event rates were low and outcomes were similar between the groups [
         <a href="#rid24">
          24
         </a>
         ]. For distal embolic protection and proximal balloon occlusion these were, respectively:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stroke or death: 3.7 and 3.2 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stroke: 2.5 and 2.4 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Death: 1.5 and 1.1 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Transient ischemic attack: 1.5 and 1.7 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Myocardial infarction (MI): 0.6 and 0.4 percent
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1519116302">
         <span class="h4">
          Microembolization
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is increasing interest in quantifying microembolization events during and following CAS, but their clinical significance has yet to be established. Ischemic brain lesions discovered on DW-MRI after CAS may be associated with an increased risk for recurrent cerebrovascular events [
         <a href="#rid43">
          43
         </a>
         ]. The number of events detected ranges widely between 33 and 72 percent and may be lower with use of EPDs [
         <a href="#rid44">
          44
         </a>
         ]. Some have suggested that proximal flow reversal devices may cause less stent-related microembolization, but this is debated [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a systematic review of observational studies that included nearly 700 patients, the rate of new ipsilateral lesions on DW-MRI was lower for CAS procedures using an EPD compared with those without an EPD (33 versus 45 percent) [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         However, in a sub-study of the ICSS trial, more patients assigned to CAS at centers using EPDs had at least one new lesion on DW-MRI (largely asymptomatic) compared with those assigned to CAS at centers where EPDs were not used (37 of 51 [73 percent] versus 25 of 73 [34 percent]) [
         <a href="#rid36">
          36,47,48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A small review evaluated the number of microembolic signals detected by transcranial Doppler or the number of new lesions identified on DW-MRI in patients undergoing flow reversal compared with filter-type EPDs, or no filter [
         <a href="#rid49">
          49
         </a>
         ]. Flow reversal was associated with fewer microembolic signals during the procedure relative to historic controls with filter protection.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3921281928">
         <span class="h1">
          CAROTID REVASCULARIZATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Carotid artery stenosis most commonly results from atherosclerotic degeneration. Disease in the carotid arteries can lead to embolization or thrombosis, resulting in neurologic events (eg, transient ischemia attack, stroke). The treatment of carotid stenosis includes maximal medical therapy and carotid revascularization for patients with appropriate indications. (See
         <a class="medical medical_review" href="/z/d/html/1106.html" rel="external">
          "Management of symptomatic carotid atherosclerotic disease", section on 'Intensive medical management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1113.html" rel="external">
          "Management of asymptomatic extracranial carotid atherosclerotic disease", section on 'Intensive medical therapy and follow-up'
         </a>
         .)
        </p>
        <p>
         The general indications for carotid revascularization for stenotic atherosclerotic lesions are the same, regardless of revascularization approach (carotid endarterectomy [CEA], transfemoral CAS [TF-CAS], transcarotid artery revascularization [TCAR]). Indications in patients with asymptomatic or symptomatic carotid artery stenosis, whether to proceed with CEA or CAS, and whether one approach to CAS is preferable over another are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1113.html" rel="external">
          "Management of asymptomatic extracranial carotid atherosclerotic disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1106.html" rel="external">
          "Management of symptomatic carotid atherosclerotic disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1104.html" rel="external">
          "Overview of carotid artery stenting", section on 'Approach to carotid artery stenting'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H51426930">
         <span class="h2">
          Contraindications for transfemoral approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Contraindications to CAS can be grouped into those that contraindicate the procedure, in general, and those that contraindicate a specific approach [
         <a href="#rid50">
          50
         </a>
         ]:
        </p>
        <p>
         Absolute contraindications to CAS (regardless of approach) include the following (see
         <a class="medical medical_review" href="/z/d/html/1104.html" rel="external">
          "Overview of carotid artery stenting", section on 'Contraindications'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Visible thrombus within the lesion detected on preoperative or intraoperative imaging (eg, ultrasound, angiography)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inability to gain vascular access
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Active infection
        </p>
        <p>
        </p>
        <p>
         Relative complications to CAS include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe carotid plaque calcification, circumferential carotid plaque
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe carotid tortuosity
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Near occlusion of the carotid artery  (
         <a class="graphic graphic_figure graphicRef129242" href="/z/d/graphic/129242.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid51">
          51,52
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Small internal carotid artery (unable to accommodate available commercial carotid stents)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients undergoing TF-CAS, the following may also preclude the ability to safely deliver the devices necessary to perform the procedure:
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age &gt;80 years (possibly a surrogate for a more heavily diseased aortic arch)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Heavily calcified, severely ulcerated or thrombus-lined aortic arch
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inability to track and deploy a cerebral protection device because of marked tortuosity of the proximal internal carotid artery
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with marked truncal obesity; colonization of groins with bacteria or yeast
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tortuous aortic arch (eg, type III arch) or aberrant arch anatomy (eg, bovine arch)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H806294048">
         <span class="h1">
          PATIENT PREPARATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The preparatory management for CAS is similar regardless of technique. Preoperative imaging, considerations for anesthesia, and prophylactic measures (eg, antibiotics) are reviewed separately. Medication management specific to transfemoral CAS (TF-CAS) is reviewed below. (See
         <a class="medical medical_review" href="/z/d/html/1104.html" rel="external">
          "Overview of carotid artery stenting", section on 'Medication management'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2958277368">
         <span class="h2">
          Antiplatelet/statin therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dual antiplatelet (DAPT) using
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         and statin therapy are recommended for all patients prior to undergoing TF-CAS. The efficacy of DAPT and statin therapy are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/1104.html" rel="external">
          "Overview of carotid artery stenting", section on 'Dual antiplatelet therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1104.html" rel="external">
          "Overview of carotid artery stenting", section on 'Statin therapy'
         </a>
         .)
        </p>
        <p>
         We use the regimen from the Carotid Revascularization Endarterectomy versus Stent Trial (CREST) [
         <a href="#rid53">
          53
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For those patients not on chronic
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         therapy, we start aspirin (325 mg twice daily) at least 48 hours before the procedure, or, if within 48 hours of the procedure, we give a loading dose of aspirin 650 mg four or more hours before the procedure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For those patients not on chronic
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         therapy, we start clopidogrel 75 mg twice daily at least 48 hours before the procedure, or if within 48 hours of the procedure, we give a loading dose of clopidogrel 450 mg four or more hours before the procedure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For those patients not on chronic statin therapy, we start
         <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">
          atorvastatin
         </a>
         40 mg daily for seven days before the procedure
         <strong>
          or
         </strong>
         we give a loading dose of 80 mg 12 hours before the procedure.
        </p>
        <p>
        </p>
        <p>
         For TF-CAS, guidelines have supported a range of periprocedural
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         therapy from 75 mg to 325 mg daily [
         <a href="#rid54">
          54,55
         </a>
         ].
        </p>
        <p>
         Following the CAS procedure, DAPT is continued for at least four weeks. We provide
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         325 mg daily
         <strong>
          plus
         </strong>
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         75 mg once daily. For patients with a history of neck irradiation, we continue DAPT indefinitely. For all other patients after CAS, we continue aspirin 325 mg daily (range 75 to 325 mg) indefinitely.
        </p>
        <p class="headingAnchor" id="H534324252">
         <span class="h1">
          TECHNIQUES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Transfemoral CAS (TF-CAS) can be performed in an angiography suite or appropriately equipped operating room with a mobile fluoroscopy unit.
        </p>
        <p>
         Complications of CAS may be directly related to the length of the CAS procedure. CAS should be performed expeditiously; if technical roadblocks are encountered (such as challenging aortic arch anatomy or extreme tortuosity that makes it difficult to insert the platform), it is very appropriate to abort the procedure. (See
         <a class="local">
          'Complications'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2296256898">
         <span class="h2">
          Percutaneous vascular access
         </span>
         <span class="headingEndMark">
          —
         </span>
         Percutaneous access is most commonly obtained via the right (or left) common femoral artery, but transaxillary, transbrachial, transradial, and transcervical percutaneous access have all been described [
         <a href="#rid56">
          56-78
         </a>
         ]. Percutaneous access is obtained in the standard fashion using ultrasound guidance. (See
         <a class="medical medical_review" href="/z/d/html/15192.html" rel="external">
          "Percutaneous arterial access techniques for diagnostic or interventional procedures"
         </a>
         .)
        </p>
        <p>
         After obtaining access, an arch aortogram should be performed unless the arch anatomy is already known from preoperative imaging, such as computed tomographic (CT) angiography or magnetic resonance (MR) angiography. Older patients may have significant atherosclerotic disease of the aortic arch and origin vessels increasing their risk for atheroembolism.
        </p>
        <p>
         Selective cerebral arteriography is also performed. Cerebral arteriography following CAS is compared with that obtained before the stent is placed to evaluate for any distal embolic debris.
        </p>
        <p class="headingAnchor" id="H2122648304">
         <span class="h2">
          Anticoagulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Before manipulation of the guidewires and catheters within the aortic arch and carotid artery, the patient should be anticoagulated (heparin or an alternative agent) to maintain the activated whole blood clotting time at 250 to 300 seconds. For patients who cannot receive heparin (eg, heparin-induced thrombocytopenia),
         <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">
          bivalirudin
         </a>
         is an alternative and may be associated with a lower incidence of bleeding compared with heparin [
         <a href="#rid79">
          79-82
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">
          "Heparin and LMW heparin: Dosing and adverse effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">
          "Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Bivalirudin'
         </a>
         .)
        </p>
        <p>
         Whether to reverse heparin with protamine at the end of the procedure is generally driven by issues pertaining to the percutaneous access site. The increased use of closure devices reduces the need for reversal; however, for patients in whom a closure device is not used at a femoral access site, reversal of anticoagulation reduces sheath dwell time and duration of bedrest. In a review from the Vascular Quality Initiative, among over 17,000 patients who underwent transfemoral carotid artery stenting, 15 percent received protamine [
         <a href="#rid83">
          83
         </a>
         ]. The use of protamine was not associated with significant differences in perioperative complications (eg, bleeding requiring reintervention, blood transfusion, transient ischemic attack, stroke, myocardial infarction, death, others) compared with no protamine. For patients treated for symptomatic carotid disease, protamine was associated with lower risk of stroke or death (3 versus 4.3 percent; relative risk 0.69, 95% CI 0.47-0.99), a difference that was not seen for asymptomatic patients.
        </p>
        <p class="headingAnchor" id="H4171421391">
         <span class="h2">
          Embolic protection device placement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Following placement of a sheath into the common carotid artery, embolic protection devices (EPDs) are deployed and then removed once the carotid artery stent has been positioned, deployed, and expanded [
         <a href="#rid84">
          84
         </a>
         ]. Two general types of EPDs (distal filter or proximal occlusion) are discussed above. (See
         <a class="local">
          'Embolic protection devices'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For protection using a distal filter, the filter is either deployed over a wire that is placed across the lesion or the filter is built into the wire and deployed after it crosses the lesion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For protection using proximal occlusion and flow occlusion designs, the occlusion balloons are placed prior to crossing the lesion.
        </p>
        <p>
        </p>
        <p>
         Distal filter devices require "unprotected" tracking over a wire, through the stenotic lesion to be treated, and are deployed in the distal internal carotid artery. The most common technical problem associated with filter devices is maneuvering them up into a tortuous distal internal carotid artery. Various techniques can be used to assist in straightening the internal carotid artery (eg, use of a "buddy" wire). Another difficulty that may be encountered is passing a filter-type EPD through a severely stenotic internal carotid artery. Predilation of the lesion can be performed; however, without a filter in place, unprotected predilation is a recognized risk factor for periprocedural stroke. Vasospasm associated with the device can also be problematic.
        </p>
        <p class="headingAnchor" id="H1814912068">
         <span class="h2">
          Stent positioning and dilation
         </span>
         <span class="headingEndMark">
          —
         </span>
         With the EPD in position, the carotid artery stenosis is predilated (if needed) and the carotid stent positioned and then deployed [
         <a href="#rid85">
          85
         </a>
         ]. A post-stenting angioplasty is performed within the stent to ensure its full deployment and apposition against the arterial wall, though the need to do so routinely has been questioned [
         <a href="#rid86">
          86-88
         </a>
         ]. Bradycardia due to baroreceptor activation can occur and lead to hypotension. The reaction is usually transient but may require the administration of
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         . Prophylactic administration of
         <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">
          glycopyrrolate
         </a>
         , an antimuscarinic anticholinergic agent, may prevent the hemodynamic response seen during carotid bulb manipulation. We give 0.2 mg glycopyrrolate intravenously prior to balloon dilation and provide a repeat dose of 0.2 mg, if necessary. (See
         <a class="medical medical_review" href="/z/d/html/90608.html" rel="external">
          "Anesthesia for carotid endarterectomy and carotid stenting", section on 'Hemodynamic monitoring'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3588939865">
         <span class="h2">
          Completion arteriography
         </span>
         <span class="headingEndMark">
          —
         </span>
         Repeat carotid arteriography is performed before and after removal of the EPD, with attention not only to the carotid lesion but also the intracranial internal carotid vessels. Carotid arteriography should demonstrate brisk flow through the previously stenotic carotid artery.
        </p>
        <p class="headingAnchor" id="H2966137964">
         <span class="h1">
          POSTPROCEDURE CARE AND FOLLOW-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many vascular surgeons will reverse heparin at the completion of a carotid endarterectomy (CEA); this can also be done at the completion of CAS. This allows normalization of activated whole blood clotting time to facilitate removing the access sheath(s). Alternatively, arterial closure devices can be used to reduce sheath dwell times and without the need for heparin reversal. (See
         <a class="local">
          'Anticoagulation'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/15192.html" rel="external">
          "Percutaneous arterial access techniques for diagnostic or interventional procedures", section on 'Hemostasis at the access site'
         </a>
         .)
        </p>
        <p>
         Postprocedure monitoring following CAS is similar to CEA. Following CAS, the patient is transferred to a monitored setting for frequent blood pressure and neurologic assessment. The importance of tight blood pressure control cannot be overemphasized. Dual antiplatelet and statin therapy should be continued postprocedure. (See
         <a class="local">
          'Antiplatelet/statin therapy'
         </a>
         above.)
        </p>
        <p>
         Routine duplex imaging is performed to identify restenosis. (See
         <a class="medical medical_review" href="/z/d/html/1104.html" rel="external">
          "Overview of carotid artery stenting", section on 'Postprocedure care and duplex surveillance'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H74250147">
         <span class="h1">
          COMPLICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most serious acute complication associated with CAS is stroke. For transfemoral CAS (TF-CAS), the stroke rate is 3 to 4 percent and has steadily decreased with improvements in device technology and operator experience [
         <a href="#rid89">
          89
         </a>
         ]. Stroke and other complications that are not specific to the approach to stenting, such as myocardial infarction, renal failure related to intravenous contrast, carotid thrombosis and restenosis, and stent fracture are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/1104.html" rel="external">
          "Overview of carotid artery stenting", section on 'Complications'
         </a>
         .)
        </p>
        <p>
         Access-related issues are the most common complications following TF-CAS and include hematoma, bleeding, pseudoaneurysm formation, and atheroembolization to the lower extremities. Following percutaneous access procedures, inadequate closure of the femoral artery puncture site may lead to bleeding, hematoma, or the formation of a pseudoaneurysm. In a review of the Vascular Quality Initiative, bleeding complications occurred in 3.8 percent; however, only 0.8 percent required intervention [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p>
         The incidence of femoral pseudoaneurysm is approximately 3 percent [
         <a href="#rid90">
          90-92
         </a>
         ]. While the narrow profile of most carotid stenting devices requires a smaller sheath size compared with some vascular interventions (eg, iliac artery stenting), it might be expected that the incidence of pseudoaneurysm might lower; however, the concomitant administration of antiplatelet therapy and anticoagulation contributes to pseudoaneurysm formation. Risk factors associated with pseudoaneurysm include inadequate postprocedure compression of the puncture site, postprocedural anticoagulation, antiplatelet therapy during the intervention, age &gt;65 years, obesity, hypertension, peripheral artery disease, and hemodialysis. The diagnosis and treatment of access site pseudoaneurysm are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/113181.html" rel="external">
          "Femoral artery pseudoaneurysm following percutaneous intervention"
         </a>
         .)
        </p>
        <p>
         During any aortic catheterization procedure, atheromatous debris can become dislodged from the aortic wall. Clinical symptoms and signs are dependent upon the size of the debris and are reviewed in detail separately.
        </p>
        <p class="headingAnchor" id="H3329614416">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/117201.html" rel="external">
          "Society guideline links: Occlusive carotid, aortic, renal, mesenteric, and peripheral atherosclerotic disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H827557069">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15819.html" rel="external">
          "Patient education: Carotid artery disease (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2895076739">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Carotid revascularization to treat carotid atherosclerotic disease can be accomplished using open surgery (carotid endarterectomy) or using a carotid artery stent (CAS), with the most common CAS approach using a percutaneous approach. Transfemoral carotid artery stenting (TF-CAS) involves accessing the femoral artery percutaneously to place the necessary guidewires and sheaths, traversing the aortic arch to gain access to the carotid artery, deployment of an embolic protection device, and subsequently dilation of the artery and placement of the stent. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Carotid revascularization'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients in whom CAS is scheduled or anticipated, dual antiplatelet therapy (DAPT) using
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         is recommended. Furthermore, periprocedural statin therapy is also recommended. (See
         <a class="local">
          'Patient preparation'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1104.html" rel="external">
          "Overview of carotid artery stenting", section on 'Summary and recommendations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For percutaneous CAS (transfemoral or other percutaneous approach), we use the following regimen, which is generally consistent with multidisciplinary guidelines:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For those patients not on chronic
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         therapy, we start aspirin (325 mg twice daily) at least 48 hours before the procedure, or, if within 48 hours of the procedure, we give a loading dose of aspirin 650 mg four or more hours before the procedure.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For those patients not on chronic
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         therapy, we start clopidogrel 75 mg twice daily at least 48 hours before the procedure, or if within 48 hours of the procedure, we give a loading dose of clopidogrel 450 mg four or more hours before the procedure.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For those patients not on chronic statin therapy, we start
         <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">
          atorvastatin
         </a>
         40 mg daily for seven days before the procedure
         <strong>
          or
         </strong>
         we give a loading dose of 80 mg 12 hours before the procedure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Following percutaneous access and sheath placement, the patient is systemically anticoagulated, typically using heparin. Whether to reverse heparin with protamine is left to the discretion of the operator and generally based on issues pertaining to the percutaneous access site. For those in whom a vascular closure device will not be used at a femoral access site, we suggest reversal of anticoagulation (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Reversal of anticoagulation reduces sheath dwell time and duration of bedrest. (See
         <a class="local">
          'Anticoagulation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Following the CAS procedure, DAPT with
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         (325 mg once daily)
         <strong>
          plus
         </strong>
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         (75 mg once daily) is continued for at least four weeks. For patients with a history of neck irradiation, we continue DAPT indefinitely. For all other patients, after clopidogrel is discontinued, we continue aspirin 325 mg daily indefinitely. (See
         <a class="medical medical_review" href="/z/d/html/1104.html" rel="external">
          "Overview of carotid artery stenting", section on 'Dual antiplatelet therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Several types of embolic protection devices (EPDs) are available and are intended to prevent embolic complications of angioplasty and stenting. Filter devices are used in most percutaneous CAS procedures. Although a benefit for EPDs has not been definitively established, many consider the use of an EPD to be standard of care. In the United States, the use of an EPD is mandatory for reimbursement for CAS. (See
         <a class="local">
          'Embolic protection devices'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The most serious acute complication associated with CAS is stroke, which can occur due to thromboembolism, hypoperfusion, hyperperfusion syndrome, or hemorrhage. The overall stroke rate for TF-CAS is 3 to 4 percent and has steadily decreased with improvements in device technology and operator experience. Other complications associated with CAS include access-related issues (eg, hematoma, bleeding, pseudoaneurysm formation, and distal atheroembolization), myocardial infarction, contrast-related renal failure, restenosis of the target lesion, and carotid stent fracture. (See
         <a class="local">
          'Complications'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1104.html" rel="external">
          "Overview of carotid artery stenting", section on 'Complications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H763657215">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The editorial staff at UpToDate acknowledges Ronald M Fairman, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Yadav JS, Roubin GS, Iyer S, et al. Elective stenting of the extracranial carotid arteries. Circulation 1997; 95:376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jim J, Sicard GA. Who is unfit for carotid endarterectomy? Perspect Vasc Surg Endovasc Ther 2010; 22:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giri J, Kennedy KF, Weinberg I, et al. Comparative effectiveness of commonly used devices for carotid artery stenting: an NCDR Analysis (National Cardiovascular Data Registry). JACC Cardiovasc Interv 2014; 7:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nikas DN, Kompara G, Reimers B. Carotid stents: which is the best option? J Cardiovasc Surg (Torino) 2011; 52:779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White CJ. Carotid artery stenting. J Am Coll Cardiol 2014; 64:722.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wissgott C, Brandt-Wunderlich C, Kopetsch C, et al. Initial Clinical Results and In Vitro Testing of the New CGuard MicroNet-Covered "One-Size-Fits-All" Carotid Stent. J Endovasc Ther 2019; 26:578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schofer J, Musiałek P, Bijuklic K, et al. A Prospective, Multicenter Study of a Novel Mesh-Covered Carotid Stent: The CGuard CARENET Trial (Carotid Embolic Protection Using MicroNet). JACC Cardiovasc Interv 2015; 8:1229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karpenko A, Bugurov S, Ignatenko P, et al. Randomized Controlled Trial of Conventional Versus MicroNet-Covered Stent in Carotid Artery Revascularization. JACC Cardiovasc Interv 2021; 14:2377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kouvelos GN, Patelis N, Antoniou GA, et al. Meta-analysis of the Effect of Stent Design on 30-Day Outcome After Carotid Artery Stenting. J Endovasc Ther 2015; 22:789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Müller MD, Gregson J, McCabe DJH, et al. Stent Design, Restenosis and Recurrent Stroke After Carotid Artery Stenting in the International Carotid Stenting Study. Stroke 2019; 50:3013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jim J, Rubin BG, Landis GS, et al. Society for Vascular Surgery Vascular Registry evaluation of stent cell design on carotid artery stenting outcomes. J Vasc Surg 2011; 54:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tadros RO, Spyris CT, Vouyouka AG, et al. Comparing the embolic potential of open and closed cell stents during carotid angioplasty and stenting. J Vasc Surg 2012; 56:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneider PA, Levy E, Bacharach JM, et al. A First-in-Human Evaluation of a Novel Mesh-Covered Stent for Treatment of Carotid Stenosis in Patients at High Risk for Endarterectomy: 30-Day Results of the SCAFFOLD Trial. JACC Cardiovasc Interv 2018; 11:2396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stabile E, de Donato G, Musialek P, et al. Use of Dual-Layered Stents in Endovascular Treatment of Extracranial Stenosis of the Internal Carotid Artery: Results of a Patient-Based Meta-Analysis of 4 Clinical Studies. JACC Cardiovasc Interv 2018; 11:2405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mousa AY, Campbell JE, Aburahma AF, Bates MC. Current update of cerebral embolic protection devices. J Vasc Surg 2012; 56:1429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonati LH, Lyrer P, Ederle J, et al. Percutaneous transluminal balloon angioplasty and stenting for carotid artery stenosis. Cochrane Database Syst Rev 2012; :CD000515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bornak A, Milner R. Current debate on the role of embolic protection devices. Vasc Endovascular Surg 2012; 46:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bijuklic K, Wandler A, Hazizi F, Schofer J. The PROFI study (Prevention of Cerebral Embolization by Proximal Balloon Occlusion Compared to Filter Protection During Carotid Artery Stenting): a prospective randomized trial. J Am Coll Cardiol 2012; 59:1383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsumura JS, Gray W, Chaturvedi S, et al. Results of carotid artery stenting with distal embolic protection with improved systems: Protected Carotid Artery Stenting in Patients at High Risk for Carotid Endarterectomy (PROTECT) trial. J Vasc Surg 2012; 55:968.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macdonald S. The evidence for cerebral protection: an analysis and summary of the literature. Eur J Radiol 2006; 60:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garg N, Karagiorgos N, Pisimisis GT, et al. Cerebral protection devices reduce periprocedural strokes during carotid angioplasty and stenting: a systematic review of the current literature. J Endovasc Ther 2009; 16:412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macdonald S. New embolic protection devices: a review. J Cardiovasc Surg (Torino) 2011; 52:821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macdonald S. Embolic protection in carotid artery stenting: "a no-brainer"? J Cardiovasc Surg (Torino) 2010; 51:861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liang P, Soden P, Wyers MC, et al. The role of transfemoral carotid artery stenting with proximal balloon occlusion embolic protection in the contemporary endovascular management of carotid artery stenosis. J Vasc Surg 2020; 72:1701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stabile E, Sannino A, Schiattarella GG, et al. Cerebral embolic lesions detected with diffusion-weighted magnetic resonance imaging following carotid artery stenting: a meta-analysis of 8 studies comparing filter cerebral protection and proximal balloon occlusion. JACC Cardiovasc Interv 2014; 7:1177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown MM. Carotid artery stenting--evolution of a technique to rival carotid endarterectomy. Am J Med 2004; 116:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheinert D, Reimers B, Cremonesi A, et al. Independent Modular Filter for Embolic Protection in Carotid Stenting. Circ Cardiovasc Interv 2017; 10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bersin RM, Stabile E, Ansel GM, et al. A meta-analysis of proximal occlusion device outcomes in carotid artery stenting. Catheter Cardiovasc Interv 2012; 80:1072.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alpaslan A, Wintermark M, Pintér L, et al. Transcarotid Artery Revascularization With Flow Reversal. J Endovasc Ther 2017; 24:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ansel GM, Hopkins LN, Jaff MR, et al. Safety and effectiveness of the INVATEC MO.MA proximal cerebral protection device during carotid artery stenting: results from the ARMOUR pivotal trial. Catheter Cardiovasc Interv 2010; 76:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clair DG, Hopkins LN, Mehta M, et al. Neuroprotection during carotid artery stenting using the GORE flow reversal system: 30-day outcomes in the EMPiRE Clinical Study. Catheter Cardiovasc Interv 2011; 77:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giugliano G, Stabile E, Biamino G, et al. Predictors of carotid occlusion intolerance during proximal protected carotid artery stenting. JACC Cardiovasc Interv 2014; 7:1237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwolek CJ, Jaff MR, Leal JI, et al. Results of the ROADSTER multicenter trial of transcarotid stenting with dynamic flow reversal. J Vasc Surg 2015; 62:1227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           SPACE Collaborative Group, Ringleb PA, Allenberg J, et al. 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. Lancet 2006; 368:1239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mas JL, Chatellier G, Beyssen B, et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med 2006; 355:1660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonati LH, Jongen LM, Haller S, et al. New ischaemic brain lesions on MRI after stenting or endarterectomy for symptomatic carotid stenosis: a substudy of the International Carotid Stenting Study (ICSS). Lancet Neurol 2010; 9:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ederle J, Featherstone RL, Brown MM. Percutaneous transluminal angioplasty and stenting for carotid artery stenosis. Cochrane Database Syst Rev 2007; :CD000515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mas JL, Trinquart L, Leys D, et al. Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial: results up to 4 years from a randomised, multicentre trial. Lancet Neurol 2008; 7:885.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tübler T, Schlüter M, Dirsch O, et al. Balloon-protected carotid artery stenting: relationship of periprocedural neurological complications with the size of particulate debris. Circulation 2001; 104:2791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vos JA, van den Berg JC, Ernst SM, et al. Carotid angioplasty and stent placement: comparison of transcranial Doppler US data and clinical outcome with and without filtering cerebral protection devices in 509 patients. Radiology 2005; 234:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roubin GS, New G, Iyer SS, et al. Immediate and late clinical outcomes of carotid artery stenting in patients with symptomatic and asymptomatic carotid artery stenosis: a 5-year prospective analysis. Circulation 2001; 103:532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Badheka AO, Chothani A, Panaich SS, et al. Impact of symptoms, gender, co-morbidities, and operator volume on outcome of carotid artery stenting (from the Nationwide Inpatient Sample [2006 to 2010]). Am J Cardiol 2014; 114:933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gensicke H, van der Worp HB, Nederkoorn PJ, et al. Ischemic brain lesions after carotid artery stenting increase future cerebrovascular risk. J Am Coll Cardiol 2015; 65:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rapp JH, Wakil L, Sawhney R, et al. Subclinical embolization after carotid artery stenting: new lesions on diffusion-weighted magnetic resonance imaging occur postprocedure. J Vasc Surg 2007; 45:867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castro-Afonso LH, Abud LG, Rolo JG, et al. Flow reversal versus filter protection: a pilot carotid artery stenting randomized trial. Circ Cardiovasc Interv 2013; 6:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schnaudigel S, Gröschel K, Pilgram SM, Kastrup A. New brain lesions after carotid stenting versus carotid endarterectomy: a systematic review of the literature. Stroke 2008; 39:1911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           International Carotid Stenting Study investigators, Ederle J, Dobson J, et al. Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial. Lancet 2010; 375:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonati LH, Gregson J, Dobson J, et al. Restenosis and risk of stroke after stenting or endarterectomy for symptomatic carotid stenosis in the International Carotid Stenting Study (ICSS): secondary analysis of a randomised trial. Lancet Neurol 2018; 17:587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goode SD, Hoggard N, Macdonald S, et al. Assessment of reverse flow as a means of cerebral protection during carotid artery stent placement with diffusion-weighted and transcranial Doppler imaging. J Vasc Interv Radiol 2013; 24:528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White CJ, Ramee SR, Collins TJ, et al. Carotid stents to prevent stroke: a nonsurgical option. Ochsner J 2003; 5:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johansson E, Fox AJ. Carotid Near-Occlusion: A Comprehensive Review, Part 1--Definition, Terminology, and Diagnosis. AJNR Am J Neuroradiol 2016; 37:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johansson E, Fox AJ. Carotid Near-Occlusion: A Comprehensive Review, Part 2--Prognosis and Treatment, Pathophysiology, Confusions, and Areas for Improvement. AJNR Am J Neuroradiol 2016; 37:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brott TG, Hobson RW 2nd, Howard G, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010; 363:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liapis CD, Bell PR, Mikhailidis D, et al. ESVS guidelines. Invasive treatment for carotid stenosis: indications, techniques. Eur J Vasc Endovasc Surg 2009; 37:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brott TG, Halperin JL, Abbara S, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease. Stroke 2011; 42:e464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pinter L, Ribo M, Loh C, et al. Safety and feasibility of a novel transcervical access neuroprotection system for carotid artery stenting in the PROOF Study. J Vasc Surg 2011; 54:1317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alvarez B, Matas M, Ribo M, et al. Transcervical carotid stenting with flow reversal is a safe technique for high-risk patients older than 70 years. J Vasc Surg 2012; 55:978.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leal I, Orgaz A, Flores Á, et al. A diffusion-weighted magnetic resonance imaging-based study of transcervical carotid stenting with flow reversal versus transfemoral filter protection. J Vasc Surg 2012; 56:1585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sfyroeras GS, Moulakakis KG, Markatis F, et al. Results of carotid artery stenting with transcervical access. J Vasc Surg 2013; 58:1402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsuda Y, Terada T, Masuo O, et al. The clinical results of transcervical carotid artery stenting and frequency chosen as the approach route of carotid artery stenting in 1,067 consecutive cases. Acta Neurochir (Wien) 2013; 155:1575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ortega G, Álvarez B, Quintana M, et al. Cognitive improvement in patients with severe carotid artery stenosis after transcervical stenting with protective flow reversal. Cerebrovasc Dis 2013; 35:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christopoulos D, Philippov E. The results of a simplified technique for safe carotid stenting in the elderly. J Vasc Surg 2011; 54:1637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palombo G, Stella N, Faraglia V, et al. Cervical access for filter-protected carotid artery stenting: a useful tool to reduce cerebral embolisation. Eur J Vasc Endovasc Surg 2010; 39:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christopoulos D, Philippov E, Kallintzi M. Safe carotid artery angioplasty and stenting in patients unsuitable for transfemoral approach. Int Angiol 2010; 29:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flores A, Doblas M, Criado E. Transcervical carotid artery stenting with flow reversal eliminates emboli during stenting: why does it work and what are the advantages with this approach. J Cardiovasc Surg (Torino) 2009; 50:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faraglia V, Palombo G, Stella N, et al. Cerebral embolization during transcervical carotid stenting with flow reversal: a diffusion-weighted magnetic resonance study. Ann Vasc Surg 2009; 23:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Criado E, Fontcuberta J, Orgaz A, et al. Transcervical carotid stenting with carotid artery flow reversal: 3-year follow-up of 103 stents. J Vasc Surg 2007; 46:864.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matas M, Alvarez B, Ribo M, et al. Transcervical carotid stenting with flow reversal protection: experience in high-risk patients. J Vasc Surg 2007; 46:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexandrescu V, Ngongang C, Proumen J, et al. Filter-protected carotid stenting via a minimal cervical access with transitory aspirated reversed flow during initial passage of the target lesion. J Endovasc Ther 2006; 13:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin JC, Kolvenbach RR, Pinter L. Protected carotid artery stenting and angioplasty via transfemoral versus transcervical approaches. Vasc Endovascular Surg 2005; 39:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pipinos II, Johanning JM, Pham CN, et al. Transcervical approach with protective flow reversal for carotid angioplasty and stenting. J Endovasc Ther 2005; 12:446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lo CH, Doblas M, Criado E. Advantages and indications of transcervical carotid artery stenting with carotid flow reversal. J Cardiovasc Surg (Torino) 2005; 46:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Criado E, Doblas M, Fontcuberta J, et al. Transcervical carotid stenting with internal carotid artery flow reversal: feasibility and preliminary results. J Vasc Surg 2004; 40:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang DW, Schubart PJ, Veith FJ, Zarins CK. A new approach to carotid angioplasty and stenting with transcervical occlusion and protective shunting: Why it may be a better carotid artery intervention. J Vasc Surg 2004; 39:994.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kedev S, Petkoska D, Zafirovska B, et al. Safety of Slender 5Fr Transradial Approach for Carotid Artery Stenting With a Novel Nitinol Double-Layer Micromesh Stent. Am J Cardiol 2015; 116:977.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lorenzoni R, Roffi M. Transradial access for peripheral and cerebrovascular interventions. J Invasive Cardiol 2013; 25:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Etxegoien N, Rhyne D, Kedev S, et al. The transradial approach for carotid artery stenting. Catheter Cardiovasc Interv 2012; 80:1081.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruzsa Z, Nemes B, Pintér L, et al. A randomised comparison of transradial and transfemoral approach for carotid artery stenting: RADCAR (RADial access for CARotid artery stenting) study. EuroIntervention 2014; 10:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stabile E, Sorropago G, Tesorio T, et al. Heparin versus bivalirudin for carotid artery stenting using proximal endovascular clamping for neuroprotection: results from a prospective randomized study. J Vasc Surg 2010; 52:1505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cogar BD, Wayangankar SA, Abu-Fadel M, et al. Clinical safety of bivalirudin in patients undergoing carotid stenting. J Invasive Cardiol 2012; 24:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Omran J, Abdullah O, Abu-Fadel M, et al. Hemorrhagic and ischemic outcomes of Heparin vs. Bivalirudin in carotid artery stenting: A meta-analysis of studies. Catheter Cardiovasc Interv 2017; 89:746.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wayangankar SA, Abu-Fadel MS, Aronow HD, et al. Hemorrhagic and ischemic outcomes after bivalirudin versus unfractionated heparin during carotid artery stenting: a propensity score analysis from the NCDR. Circ Cardiovasc Interv 2013; 6:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liang P, Motaganahalli R, Swerdlow NJ, et al. Protamine use in transfemoral carotid artery stenting is not associated with an increased risk of thromboembolic events. J Vasc Surg 2021; 73:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zahn R, Mark B, Niedermaier N, et al. Embolic protection devices for carotid artery stenting: better results than stenting without protection? Eur Heart J 2004; 25:1550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): a randomised trial. Lancet 2001; 357:1729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spacek M, Zimolova P, Veselka J. Carotid artery stenting without post-dilation. J Interv Cardiol 2012; 25:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Öcal L, Küp A, Çelik M, et al. What should be the Optimal Carotid Stent Opening Rate Without Post-Dilation? J Stroke Cerebrovasc Dis 2020; 29:105155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ogata A, Sonobe M, Kato N, et al. Carotid artery stenting without post-stenting balloon dilatation. J Neurointerv Surg 2014; 6:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malas MB, Dakour-Aridi H, Wang GJ, et al. Transcarotid artery revascularization versus transfemoral carotid artery stenting in the Society for Vascular Surgery Vascular Quality Initiative. J Vasc Surg 2019; 69:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson BM, English SJ, Fairman RM, et al. Carotid artery stenting: identification of risk factors for poor outcomes. J Vasc Surg 2008; 48:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taha MM, Sakaida H, Asakura F, et al. Access site complications with carotid angioplasty and stenting. Surg Neurol 2007; 68:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schermerhorn ML, Liang P, Eldrup-Jorgensen J, et al. Association of Transcarotid Artery Revascularization vs Transfemoral Carotid Artery Stenting With Stroke or Death Among Patients With Carotid Artery Stenosis. JAMA 2019; 322:2313.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 127412 Version 6.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9008452" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Elective stenting of the extracranial carotid arteries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20798077" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Who is unfit for carotid endarterectomy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24440025" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Comparative effectiveness of commonly used devices for carotid artery stenting: an NCDR Analysis (National Cardiovascular Data Registry).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22051987" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Carotid stents: which is the best option?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25125305" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Carotid artery stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31060430" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Initial Clinical Results and In Vitro Testing of the New CGuard MicroNet-Covered "One-Size-Fits-All" Carotid Stent.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26292586" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : A Prospective, Multicenter Study of a Novel Mesh-Covered Carotid Stent: The CGuard CARENET Trial (Carotid Embolic Protection Using MicroNet).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34736737" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Randomized Controlled Trial of Conventional Versus MicroNet-Covered Stent in Carotid Artery Revascularization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26232399" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Meta-analysis of the Effect of Stent Design on 30-Day Outcome After Carotid Artery Stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31547798" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Stent Design, Restenosis and Recurrent Stroke After Carotid Artery Stenting in the International Carotid Stenting Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21458198" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Society for Vascular Surgery Vascular Registry evaluation of stent cell design on carotid artery stenting outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22386144" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Comparing the embolic potential of open and closed cell stents during carotid angioplasty and stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30522669" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : A First-in-Human Evaluation of a Novel Mesh-Covered Stent for Treatment of Carotid Stenosis in Patients at High Risk for Endarterectomy: 30-Day Results of the SCAFFOLD Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30522670" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Use of Dual-Layered Stents in Endovascular Treatment of Extracranial Stenosis of the Internal Carotid Artery: Results of a Patient-Based Meta-Analysis of 4 Clinical Studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22885126" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Current update of cerebral embolic protection devices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22972047" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Percutaneous transluminal balloon angioplasty and stenting for carotid artery stenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22723261" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Current debate on the role of embolic protection devices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22284330" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The PROFI study (Prevention of Cerebral Embolization by Proximal Balloon Occlusion Compared to Filter Protection During Carotid Artery Stenting): a prospective randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22236885" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Results of carotid artery stenting with distal embolic protection with improved systems: Protected Carotid Artery Stenting in Patients at High Risk for Carotid Endarterectomy (PROTECT) trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16971079" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : The evidence for cerebral protection: an analysis and summary of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19702342" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Cerebral protection devices reduce periprocedural strokes during carotid angioplasty and stenting: a systematic review of the current literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22051990" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : New embolic protection devices: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21124283" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Embolic protection in carotid artery stenting: "a no-brainer"?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32251772" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The role of transfemoral carotid artery stenting with proximal balloon occlusion embolic protection in the contemporary endovascular management of carotid artery stenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25240544" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Cerebral embolic lesions detected with diffusion-weighted magnetic resonance imaging following carotid artery stenting: a meta-analysis of 8 studies comparing filter cerebral protection and proximal balloon occlusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14969656" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Carotid artery stenting--evolution of a technique to rival carotid endarterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28283511" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Independent Modular Filter for Embolic Protection in Carotid Stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22454248" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : A meta-analysis of proximal occlusion device outcomes in carotid artery stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28335706" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Transcarotid Artery Revascularization With Flow Reversal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20222019" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Safety and effectiveness of the INVATEC MO.MA proximal cerebral protection device during carotid artery stenting: results from the ARMOUR pivotal trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20853365" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Neuroprotection during carotid artery stenting using the GORE flow reversal system: 30-day outcomes in the EMPiRE Clinical Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25326744" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Predictors of carotid occlusion intolerance during proximal protected carotid artery stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26506270" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Results of the ROADSTER multicenter trial of transcarotid stenting with dynamic flow reversal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17027729" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17050890" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20189458" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : New ischaemic brain lesions on MRI after stenting or endarterectomy for symptomatic carotid stenosis: a substudy of the International Carotid Stenting Study (ICSS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17943745" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Percutaneous transluminal angioplasty and stenting for carotid artery stenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18774745" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial: results up to 4 years from a randomised, multicentre trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11733396" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Balloon-protected carotid artery stenting: relationship of periprocedural neurological complications with the size of particulate debris.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15616120" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Carotid angioplasty and stent placement: comparison of transcranial Doppler US data and clinical outcome with and without filtering cerebral protection devices in 509 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11157718" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Immediate and late clinical outcomes of carotid artery stenting in patients with symptomatic and asymptomatic carotid artery stenosis: a 5-year prospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25208563" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Impact of symptoms, gender, co-morbidities, and operator volume on outcome of carotid artery stenting (from the Nationwide Inpatient Sample [2006 to 2010]).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25677309" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Ischemic brain lesions after carotid artery stenting increase future cerebrovascular risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17376643" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Subclinical embolization after carotid artery stenting: new lesions on diffusion-weighted magnetic resonance imaging occur postprocedure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24084627" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Flow reversal versus filter protection: a pilot carotid artery stenting randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18388346" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : New brain lesions after carotid stenting versus carotid endarterectomy: a systematic review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20189239" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29861139" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Restenosis and risk of stroke after stenting or endarterectomy for symptomatic carotid stenosis in the International Carotid Stenting Study (ICSS): secondary analysis of a randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23462063" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Assessment of reverse flow as a means of cerebral protection during carotid artery stent placement with diffusion-weighted and transcranial Doppler imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22493566" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Carotid stents to prevent stroke: a nonsurgical option.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26316571" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Carotid Near-Occlusion: A Comprehensive Review, Part 1--Definition, Terminology, and Diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26338908" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Carotid Near-Occlusion: A Comprehensive Review, Part 2--Prognosis and Treatment, Pathophysiology, Confusions, and Areas for Improvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20505173" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Stenting versus endarterectomy for treatment of carotid-artery stenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19286127" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : ESVS guidelines. Invasive treatment for carotid stenosis: indications, techniques.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21282493" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21658889" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Safety and feasibility of a novel transcervical access neuroprotection system for carotid artery stenting in the PROOF Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22322116" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Transcervical carotid stenting with flow reversal is a safe technique for high-risk patients older than 70 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22960021" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : A diffusion-weighted magnetic resonance imaging-based study of transcervical carotid stenting with flow reversal versus transfemoral filter protection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24074938" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Results of carotid artery stenting with transcervical access.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23653167" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : The clinical results of transcervical carotid artery stenting and frequency chosen as the approach route of carotid artery stenting in 1,067 consecutive cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23406878" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Cognitive improvement in patients with severe carotid artery stenosis after transcervical stenting with protective flow reversal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21890307" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : The results of a simplified technique for safe carotid stenting in the elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19945315" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Cervical access for filter-protected carotid artery stenting: a useful tool to reduce cerebral embolisation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20224530" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Safe carotid artery angioplasty and stenting in patients unsuitable for transfemoral approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19935605" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Transcervical carotid artery stenting with flow reversal eliminates emboli during stenting: why does it work and what are the advantages with this approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19041221" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Cerebral embolization during transcervical carotid stenting with flow reversal: a diffusion-weighted magnetic resonance study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17980271" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Transcervical carotid stenting with carotid artery flow reversal: 3-year follow-up of 103 stents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17606121" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Transcervical carotid stenting with flow reversal protection: experience in high-risk patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16643074" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Filter-protected carotid stenting via a minimal cervical access with transitory aspirated reversed flow during initial passage of the target lesion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16382271" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Protected carotid artery stenting and angioplasty via transfemoral versus transcervical approaches.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16048376" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Transcervical approach with protective flow reversal for carotid angioplasty and stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15956920" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Advantages and indications of transcervical carotid artery stenting with carotid flow reversal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15337876" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Transcervical carotid stenting with internal carotid artery flow reversal: feasibility and preliminary results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15111851" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : A new approach to carotid angioplasty and stenting with transcervical occlusion and protective shunting: Why it may be a better carotid artery intervention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26189035" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Safety of Slender 5Fr Transradial Approach for Carotid Artery Stenting With a Novel Nitinol Double-Layer Micromesh Stent.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24088428" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Transradial access for peripheral and cerebrovascular interventions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22639455" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : The transradial approach for carotid artery stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25042266" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : A randomised comparison of transradial and transfemoral approach for carotid artery stenting: RADCAR (RADial access for CARotid artery stenting) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20719465" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Heparin versus bivalirudin for carotid artery stenting using proximal endovascular clamping for neuroprotection: results from a prospective randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22562912" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Clinical safety of bivalirudin in patients undergoing carotid stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27526953" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Hemorrhagic and ischemic outcomes of Heparin vs. Bivalirudin in carotid artery stenting: A meta-analysis of studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23532554" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Hemorrhagic and ischemic outcomes after bivalirudin versus unfractionated heparin during carotid artery stenting: a propensity score analysis from the NCDR.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32535154" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Protamine use in transfemoral carotid artery stenting is not associated with an increased risk of thromboembolic events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15342175" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Embolic protection devices for carotid artery stenting: better results than stenting without protection?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11403808" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): a randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22150803" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Carotid artery stenting without post-dilation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32912494" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : What should be the Optimal Carotid Stent Opening Rate Without Post-Dilation?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24014467" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Carotid artery stenting without post-stenting balloon dilatation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29941316" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Transcarotid artery revascularization versus transfemoral carotid artery stenting in the Society for Vascular Surgery Vascular Quality Initiative.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18502085" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Carotid artery stenting: identification of risk factors for poor outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17905068" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Access site complications with carotid angioplasty and stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31846015" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Association of Transcarotid Artery Revascularization vs Transfemoral Carotid Artery Stenting With Stroke or Death Among Patients With Carotid Artery Stenosis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
